Several injectable fillers and two wrinkle relaxers may crossover from Europe to the U.S. marketplace within the next year, as many undergo clinical trials and seek FDA approval.
These new injectables not only offer patients more choices for wrinkle reduction, volume restoration and facial rejuvenation, but also more competitive pricing and better results afforded by innovation and better technology.
New Hyaluronic Acid Fillers
Many of the new injectable fillers headed for the U.S. are composed of hyaluronic acid gel, including Belotero by Merz, a hyaluronic acid (HA) filler similar to Juvederm offered in three concentrations—soft, basic and intense.
Belotero has already been filed with the FDA and is purported to provide an improved level of tissue integration that causes fewer incidences of lumps and bumps than other hyaluronic acid fillers.
New additions to the Juvederm and Restylane families of injectable HA fillers may be headed to the U.S. as well.
Juvederm Hydrate and Restylane Vital are thinner hyaluronic acid filler formulations are used for treating areas that have been historically difficult to correct with fillers, such as the back of the hands, décolleté and neck, and both purportedly offer wrinkle prevention by boosting skin hydration and elasticity.
Unlike Juvederm Hydrate, Restylane Vital offers a specialized automatic injection pen that regulates product injection volume and speed for more precise results.
Thicker hyaluronic acid filler formulations Juvederm Voluma and Restylane SubQ are designed to add volume to large areas of the face, such as the chin and cheeks. SubQ is also reportedly used for buttock and breast augmentation.
Innovative injectables: Beyond HA fillers
In addition to the new hyaluronic acid fillers poised to enter the U.S. marketplace, injectable fillers composed of other materials may also soon be available.
Novabel, the first injectable filler composed of spherical, flexible structures called Geleons formed from marine algae extract, reportedly makes cosmetic injections virtually painless and also improves skin elasticity. The composition of Novabel is also said to make injection easier and reduce swelling, making it ideal for adding volume to thin-skinned facial areas, such as the eyelids and tear troughs.
Derma Veil, a pure collagen stimulator made of polylactic and polyglycolic acids (PLGA), is another new non-HA filler that may make its way to the U.S. If approved, Derma Veil would be use primarily for facial volume restoration and compete directly with Sculptra Aesthetic.
New botulinum type A injectables
Two new botulinum type A neurotoxins, Xeomin and PurTox, may join Botox and Dysport to become part of the arsenal of wrinkle relaxing injectables available in the U.S. In fact, PurTox has already completed clinical trials and may be closing in on FDA approval.
PurTox and Xeomin are purported to offer theoretical benefits over Botox and Dysport, such as faster, longer-lasting results and decreased possibility of allergic reaction and development of blocking antibodies. These benefits have not yet been proven, however and likely will not be explored until further testing is completed.
Tags: hyaluronic
